The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure.

Mathias, C. J.; Fosbraey, Paul; Costa, Diogo; Thornley, Andrew; Bannister, R.

doi:10.1136/bmj.293.6543.353

Cited by 187 publications

(90 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…58 The vasopressin analogue desmopressin, which acts on renal tubular vasopressin-2 receptors, reduces nocturnal polyuria and improves morning postural hypotension. 60 The peptide erythropoietin may be beneficial in some patients by raising red cell mass, secondarily improving cerebral oxygenation. 61,62 A broad range of drugs has been used in the treatment of postural hypotension.…”

Section: S38 Gk Wenning Et Almentioning

confidence: 99%

Multiple system atrophy: An update

et al. 2003

View full text Add to dashboard Cite

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-dopa) -unresponsive parkinsonism in 80% of cases (MSA-P subtype) or with cerebellar ataxia in 20% of cases (MSA-C subtype). Pathologically, MSA is characterized by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing alpha-synuclein aggregates. Pharmacological treatment of motor features is disappointing except for a transient L-dopa response in a minority of MSA-P patients. In contrast, autonomic and urogenital features of MSA should be identified early on, because they can be treated effectively in many instances. Neuroprotective strategies are presently unavailable, however, two multicentre European trials have been launched to evaluate the effects of riluzole and human recombinant growth hormone on disease progression in MSA. Clearly, further randomised, controlled trials are required to identify effective symptomatic or neuroprotective agents in MSA. Several in vivo models have become available to allow a careful preselection of candidate agents. Several research groups have been formed in Europe (EMSA-SG, NNIPPS) and United States (NAMSA-SG), providing a framework for coordinated trial activity in MSA.

show abstract

Section: S38 Gk Wenning Et Almentioning

confidence: 99%

Multiple system atrophy: An update

et al. 2003

View full text Add to dashboard Cite

show abstract

“…801 DDAVP is a synthetic vasopressin analogue that acts on the V2 receptors of renal tubular cells to promote reabsorption of water and expansion of intravascular volume. It should be noted that DDAVP can induce a severe and lifethreatening hyponatremia, and that careful monitoring of serum sodium concentration is necessary during the first 4 to 5 days of treatment and at monthly intervals thereafter.…”

Section: Impulse Dyscontrol and Dopamine Dysregulation Disordersmentioning

confidence: 99%

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow¹,

Stern²,

Sethi³

2009

Neurology

760

658

View full text Add to dashboard Cite

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older. With the aging of the population, the frequency of PD is expected to increase dramatically in the coming decades. Current therapy is largely based on a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However, chronic treatment is associated with the development of motor complications, and the disease is inexorably progressive. Further, advancing disease is associated with the emergence of features such as freezing, falling, and dementia which are not adequately controlled with dopaminergic therapies. Indeed, it is now appreciated that these nondopaminergic features are common and the major source of disability for patients with advanced disease. Many different therapeutic agents and treatment strategies have been evaluated over the past several years to try and address these unmet medical needs, and many promising approaches are currently being tested in the laboratory and in the clinic. As a result, there are now many new therapies and strategic approaches available for the treatment of the different stages of PD, with which the treating physician must be familiar in order to provide patients with optimal care. This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials. It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches. 1 PD is the second most common neurodegenerative disorder, with an average age at onset of about 60 years. An estimated 5 million people throughout the world have PD, with 1 million individuals each in the United States and in Europe with the disorder. PD affects approximately 0.3% of the population and 1% to 2% of those older than 60 years.2 With the aging of the population and the substantial increase in the number of at-risk individuals older than 60 years, it is anticipated that the prevalence of PD will increase dramatically in the coming decades.

show abstract

“…NP has been described but the times of overnight urine collection vary. Donaldson et al [12] arranged collections between 6 p.m. and 6 a.m., Wilcox et al [13] from 10 p.m. to 10 a.m. and Mathias et al [14] from bedtime to the time of getting up in the morning. For this study it was decided to standardise the collection period from midnight to 8 a.m. the next morning and NP was therefore defined as 'the production of 33% or more of the total 24-hour urine volume between midnight and 8 a.m.'.…”

Section: Introductionmentioning

confidence: 99%